SITC, Holt et al

Nov 7 – 11 2018: Washington DC

Poster presentation: Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma